Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884251 | 0.89 | HRH3 (0.50) | HRH3HTR2BMEN1KMT2AFPR2 | |
| SCHEMBL13085870 | 0.86 | HTR2B (0.51) | HRH3HTR2BMEN1KMT2A | |
| SCHEMBL2879144 | 0.81 | HPGD (0.63) | HRH3HTR2B | |
| SCHEMBL2884319 | 0.80 | HRH3 (0.68) | HRH3HTR2BMEN1KMT2A | |
| SCHEMBL2886284 | 0.80 | HRH3 (0.72) | HRH3HTR2B | |
| SCHEMBL2881259 | 0.80 | HRH3 (0.67) | HRH3HTR2B | |
| SCHEMBL1811732 | 0.79 | HRH3 (0.66) | HRH3 | |
| SCHEMBL1811730 | 0.79 | HRH3 (0.66) | HRH3 | |
| SCHEMBL1812400 | 0.77 | FGFR1 (0.51) | HRH3 | |
| SCHEMBL1812402 | 0.77 | FGFR1 (0.51) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885HTR2B 36/4885MEN1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.